Immunome Toekomstige groei

Future criteriumcontroles 2/6

Immunome zal naar verwachting groeien in winst en omzet met respectievelijk 20% en 65.1% per jaar. De winst per aandeel zal naar verwachting groeien met 28.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -73.4% zijn.

Belangrijke informatie

20.0%

Groei van de winst

28.8%

Groei van de winst per aandeel

Biotechs winstgroei	28.0%
Inkomstengroei	65.1%
Toekomstig rendement op eigen vermogen	-73.4%
Dekking van analisten	Good
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqCM:IMNM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	18	-208	-165	-118	7
12/31/2025	4	-195	-159	-147	7
12/31/2024	9	-253	-261	-107	7
9/30/2024	10	-305	-139	-86	N/A
6/30/2024	11	-263	-107	-61	N/A
3/31/2024	13	-232	-46	-43	N/A
12/31/2023	14	-107	-8	-8	N/A
9/30/2023	10	-22	3	3	N/A
6/30/2023	7	-27	4	4	N/A
3/31/2023	2	-30	2	2	N/A
12/31/2022	N/A	-38	-29	-29	N/A
9/30/2022	N/A	-38	-29	-29	N/A
6/30/2022	N/A	-36	-26	-25	N/A
3/31/2022	N/A	-32	-21	-21	N/A
12/31/2021	N/A	-25	-18	-18	N/A
9/30/2021	N/A	-21	-18	-17	N/A
6/30/2021	N/A	-22	-16	-16	N/A
3/31/2021	N/A	-19	-14	-14	N/A
12/31/2020	N/A	-18	-13	-12	N/A
9/30/2020	N/A	-17	-9	-9	N/A
6/30/2020	N/A	-11	-9	-8	N/A
3/31/2020	N/A	-11	-10	-9	N/A
12/31/2019	N/A	-10	-10	-10	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IMNM de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IMNM de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IMNM de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IMNM ( 65.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van IMNM ( 65.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IMNM binnen 3 jaar verliesgevend zal zijn.

Immunome Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Consensus EPS estimates fall by 97%, revenue upgraded

Consensus EPS estimates fall by 17%

Consensus EPS estimates upgraded to US$0.97 loss

No longer forecast to breakeven

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares